SUNNYVALE, Calif., Oct. 15,
2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL)
("Ceribell"), a commercial-stage medical technology company focused
on transforming the diagnosis and management of patients with
serious neurological conditions, announced today the closing of its
upsized initial public offering of 12,196,969 shares of its common
stock at a public offering price of $17.00 per share, which includes 1,590,909 shares
of common stock issued upon the exercise in full by the
underwriters of their option to purchase additional shares. The
total gross proceeds from the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by Ceribell, were approximately $207.3 million. All of the shares of common stock
were offered by Ceribell. Ceribell's common stock began trading on
the Nasdaq Global Select Market on October
11, 2024 under the ticker symbol "CBLL".
BofA Securities and J.P. Morgan acted as joint book-running
managers and as representatives of the underwriters for the
offering. William Blair, TD Cowen and Canaccord Genuity acted as
co-managers for the offering.
A registration statement relating to the shares sold in this
offering was filed with the Securities and Exchange Commission and
became effective on October 10, 2024.
The offering was made only by means of a prospectus, copies of
which may be obtained from BofA Securities, Attention: Prospectus
Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; or J.P. Morgan, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at
prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ceribell
Ceribell is a commercial-stage medical technology company
focused on transforming the diagnosis and management of patients
with serious neurological conditions. The Ceribell System is an
AI-powered, rapidly deployable point-of-care
electroencephalography ("EEG") platform designed to address the
unmet needs of patients in the acute care setting. The company is
headquartered in Sunnyvale,
Calif.
INVESTOR CONTACT
Brian Johnston or Laine Morgan
Gilmartin Group, LLC
investors@ceribell.com
MEDIA CONTACT
Corrie Rose
Press@ceribell.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ceribell-inc-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-302277031.html
SOURCE Ceribell, Inc.